Sirona Biochem Announces Preclinical Results of Diabetes Compound
News Feb 28, 2012
Sirona Biochem Corp. has announced that its lead compound for the treatment of Type 2 diabetes was effective in lowering blood glucose levels in a well-established preclinical diabetic model.
Sirona Biochem's compound, SBM-TFC-039, significantly and rapidly reduced the blood glucose level in obese diabetic rats (Zucker).
In an acute dosing study, six hours after treatment, the blood glucose level of obese diabetic rats was reduced to the level of control lean rats.
There was a strong correlation between the decrease in blood glucose level (0 to 6 hours post treatment) and the excretion of urinary glucose.
A study in normal rats also confirmed that SBM-TFC-039 triggered elimination of glucose through the urine (glycosuria) in a dose dependent manner.
SBM-TFC-039 also reduced blood glucose excursions following a glucose challenge by 34 percent compared to an untreated group. A separate safety study of SBM-TFC-039 showed the compound was well-tolerated.
SBM-TFC-039 is a sodium glucose transporter (SGLT) inhibitor. SGLT inhibitors are a new class of drug candidates for diabetes.
In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.
In addition to the SGLT inhibitor program, Sirona Biochem is continuing progress of its studies of skin lighteners and anti-aging agents for cosmetic use, inducers for recombinant protein production and adjuvants for cell and organ preservation.
All of the programs leverage the company's proprietary chemistry technology.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE